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1. Introduction 
Mycobacterium tuberculosis (Mtb) is a causative agent of 
tuberculosis (TB). It is a pathogen that has latently infected about one 
third of the world population. Infection occurs via aerosol, and 
inhalation of a few droplets containing Mtb bacilli is enough for lung 
infection. After infection, Mtb pathogenesis occurs in two stages. The 
first is an asymptomatic state that can persist for many years in the 
host, called latent TB. The second stage requires only a weakened 
immune response to become activated, then the bacteria begins 
replicating and causing characteristic symptoms such as cough, chest 
pain, fatigue and unexplained weight loss. If left untreated, the 
disease eventually culminates in death. The emergence of Human 
Immunodeficiency Virus (HIV) and the resultant Acquired Immune 
Deficiency Syndrome (AIDS) pandemic underlined the importance of 
reactivation of the disease and its potentially catastrophic outcome 
since over 50% of deaths among HIV infected patients results from 
co-infection with Mtb with the two pathogens inducing each other’s 
replication, thus accelerating the collapse of the immune system.[1-6] 
The World Health Organization (WHO) survey estimated that close to 
2 million deaths occur every year, that there are approximately 8 
million new cases annually, and that every third individual on the 
planet has been exposed to or infected by Mtb. Although TB can be 
treated and even cured with chemotherapy, treatment is exceedingly 
lengthy and takes 6-9 months. In addition to significant toxicity, 
lengthy therapy also causes poor patient compliance, which is a 
frequent cause for selection of drug resistant and often deadly 
multidrug resistant TB (MDR-TB) bacteria.[7-10] Currently, TB 
therapy is made up of a cocktail of first-line drugs, Isoniazid (INH), 
Rifampicin (RIF), pyrazinamide (PZA) and ethambutol, which are 
given for six months. If this treatment fails as a result of bacterial 
drug resistance or intolerance to one or more drugs, second-line 
drugs are used, such as para-aminosalicilate, kanamycin, 
fluoroquinolones, capreomycin, ethionamide and cycloserine. These 
are generally less effective or more toxic with serious side effects. 
This second-line treatment can also result ineffective since MDR-
strains that exhibit resistance to these second-line drugs are 
currently on the rise. Treatment is also made quite difficult by the 
presence of metabolically silent, persistent or dormant bacteria 
within host lesions. These are not susceptible to the anti-TB drugs 
that usually kill growing but not persistent bacteria. While there are 
many reasons for drug resistance, including prescription of 
inadequate regimens, an uncertain drug supply, and ineffective drugs, 
duration of lengthy treatments is one of the major contributors 
because some TB patients prematurely stop their therapy after an 
initial, rapid heath improvement, thereby favoring the emergence of 
drug-resistant strains.[11-15] 
 
2. Diarylquinolines 
The diarylquinoline compound Bedaquiline (TMC207 or 
R207910), first reported in 2005, is the first known anti-TB agent in 
the diarylquinoline class.[16-18] The vast research and development 
on TMC207, have contributed new related compounds.[19,20] 
TMC207 was one of the lead compounds discovered in a high-
throughput screen for compounds with activity against 
Mycobacterium smegmatis (nonpathogenic fast-growing 
mycobacterium), which were subsequently evaluated against Mtb. 
Bedaquiline is formerly known as TMC207 or R207910, 
bedaquiline is a new antibiotic belonging to the class of 
diarylquinolines with specific activity against Mtb, which has also 
shown in vitro activity against other non-tuberculous 
mycobacteria.[21,22] Bedaquiline was discovered after a high-
throughput evaluation of thousands of compounds using M. 
smegmatis in a whole-cell assay.[16] The drug showed activity 
against Mtb and then entered into clinical evaluation for drug 
susceptible and MDR-TB. Based on the results of two phase II clinical 
trials, bedaquiline has recently received conditional approval for the 
treatment of MDR-TB under the trade name Sirturo. A black box 
warning is, however, accompanying this authorization due to the 
reported unexplained deaths and QT interval prolongation.[23,24] 
Bedaquiline is also being evaluated in new combination regimens 
with the purpose of reducing the length of treatment. The mode of 
action of bedaquiline is by inhibiting the ATP synthase of Mtb, which 
was a completely new target of action for an anti-TB drug. This mode 
of action was discovered by analyzing Mtb and M. smegmatis mutants 
resistant to bedaquiline. By sequencing the genome of these mutants 
and comparing to that of the susceptible strains, the only mutation 
found was in the atpE gene, which encodes the c part of the F0 
subunit of the ATP synthase.[25] This is a complex structure that 
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generates the ATP needed by the mycobacterial cell for which 
bedaquiline has a favored specificity compared to mitochondrial ATP 
synthase.[26-28]  
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Figure 1: Structure of bedaquiline 
The most prevalent mutation in the atpE gene found in 
bedaquiline resistant mutants is A63P but also I66M has been found. 
The latter introduces a modification that interferes the proper 
binding of bedaquiline to its target.[29,30] Nevertheless, in a study to 
further assess the mechanisms of resistance to bedaquiline in Mtb, it 
was found that only 15 out of 53 resistant mutants had mutations in 
atpE. The other 38 strains lacked mutations in atpE or even in the F0 
or F1 operons, which suggests that other mechanisms of resistance 
are still possible.[22] 
Relative configuration of the two stereocenters of 
TMC207[31,32], are required for activity.[16,33] Sterically 
undemanding functional groups can be substituted for the bromine 
on the quinoline ring without significant loss of activity, although a 
bromine atom appears to be preferred. The naphthyl substituent can 
be replaced with other electron-poor aryl groups and still maintain 
good activity against Mtb. Based on initial reports, the dimethyl 
substituted tertiary amine appears to be required for activity, with 
the replacement of one methyl substituent with a proton or ethyl 
substituent resulting in a decrease in activity.[16,24] However, more 
recent reports suggest that the N-monodesmethyl metabolite of 
TMC207 produced by oxidation by CYP3A4, a cytochrome P450 that 
is potently induced by RIF, maintains significant antitubercular 
activity.[34,35] 
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Figure 2L Structure activity relationship of TMC207 
 
The TMC207 is highly specific for mycobacteria. Both 
H37Rv and clinical isolates show MICs in the range of 54–217 nM. 
TMC207 targets the c subunit of ATP synthase (atpE gene), a 
mechanism of action distinct from fluoroquinolones and other 
quinoline derivatives.[29] The tertiary amine of TMC207 serves as an 
arginine mimic, allowing the compound to disrupt the proton 
transport chain of ATP synthase.[36] Point mutations in atpE confer 
resistance; these mutations occur at a rate of one in 107 to 108, 
similar to the bacterial mutant frequency of rifampicin resistance. 
Treatment of MTb-infected mice exclusively with TMC207 at 25 
mg/kg was as effective as triple combination therapy of 
RIF/INH/PZA. Also in mice, the addition of TMC207 to standard 
MDR-TB regimens showed an improved cure rate over the standard 
regimen alone.[34,35] TMC207 acts synergistically with PZA in 
mice.[37] In guinea pigs, treatment with TMC207 for 6 weeks 
resulted in almost complete eradication of MTb bacilli from 
lesions.[38] Furthermore, TMC207 has also been shown to be 
bactericidal in vitro against non-replicating Mtb, suggesting that 
TMC207 might prove therapeutically effective against latent TB. Also, 
a once-weekly schedule of administration of TMC207/ 
rifapentine/PZA tested in mice was more active than the standard 
regimen of RIF/INH/PZA given daily.39 Because TMC207 has a long 
half-life in humans (44–64 h in plasma), once-weekly TB treatments 
might one day be possible. However, metabolism of TMC207 is 
enhanced by the presence of RIF, suggesting that coadministration of 
these drugs might not be straight forward.[33,34] 
In humans, Cmax is reached in 4–5 h, and a daily dose of 
400 mg administered daily for 7 days results in a Cmax of 10 mM. A 
steady-state concentration of 1 mM, which appears to be required for 
bactericidal activity, can be maintained with a dosing schedule of 400 
mg daily for 2 weeks followed by reduced doses of 200 mg three 
times weekly. Adverse events occurred at a low rate and side effects 
were considered mild to moderate.[24,25] The TMC207 showed 
significant bactericidal activity after 4 days of a 7-day trial treating 
previously untreated TB patients, although onset of bactericidal 
activity was delayed in comparison to RIF and INH. The TMC207 in 
combination with a standard, five-drug, second-line anti-TB regimen 
in MDR patients showed that after 8 weeks of treatment, 48% of 
study participants receiving the TMC207 regimen converted to 
negative sputum culture, compared with 9% of those on the standard 
regimen.[40] Additional trials are ongoing in MDR patients[40], and 
TMC207 is undergoing further development for drug-susceptible 
TB.[41] 
 
3. Other quinoline derivatives 
A quinoline ring is one of the moieties frequently used in 
new drug design. It has been considered a pharmacophore for the 
design of anti-TB agents. Diarilquinoline, denominated TMC207, is an 
adenosine ATP synthase inhibitor that is one of the most important 
quinoline derivatives with anti-TB activity. TMC207 is currently in 
Phase II clinical trials. Also, butanamide has been established as an 
important pharmacophore with good antibacterial activity and the 
carbohydrazone moiety is also known as a pharmacophore group. 
Based on the above, the design of new quinoline derivatives with 
active carbohydrazine and butanamide moieties in 3 and 4-position, 
respectively.[42-48] The study of these compounds shows that the 
presence of a trifluoromethyl group at 8-position increases activity; 
however, the introduction of a fluoro group in 6-position partially 
decreases activity (1) considering these type of compounds 
nontoxic.[49] Following the development of mefloquine analogs (2) 
in a series of compounds (3), good anti-TB activity has been 
attributed to the presence of pharmacologically active heterocyclic 
groups such as pyrazole, imidazole, and indole rings on the quinoline 
ring. Compounds with a hetoaromatic pyrazole ring have activity 
against resistant strains, which can be attributed to the presence of 
substituents (electron donating groups) that stabilize the pyrazole 
ring, making the quinoline ring a more active entity.[50] The 
conformational restriction-like strategy in flexible drugs is 
extensively used in medicinal chemistry. This helped determined 
steric requirements of receptor-drug interaction and identification of 
new structures with high efficiency and selectivity. Based on this, 
Goncalves et al studied the conformational restriction of the 
piperidinyl ring of mefloquine through the construction of an 
oxazolidine ring and different substituents on the phenyl ring (4). 
Conformational restriction showed that the introduction of 
an oxazolidine core in the mefloquine structure enhances anti-TB 
activity. The activity of these compounds is affected by substituents 
on the aromatic ring bound to C-17 of the oxazolidenyl nucleus. 
Compounds that show hydroxyl or methoxyl groups, which are both 
electron donators and capable of forming strong hydrogen bonds, in 
general are active. In contrast, with one exception, compounds with 
nitro or halogenated groups (electron withdrawing groups and 
capable of forming only weak hydrogen bonds), are inactive.[51] 
Thus, mefloquine has been used to design anti-TB agents, 
introduction of a hydrazone linker into mefloquine at 4-position, 
substitution of a piperidine with a piperazine ring and extension of 
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the basic terminus of the piperazine ring at 4-position. Additionally, 
isoxazole is emerging as one of the most powerful hits in high-
throughput screening (HTS) against Mtb. Both types of compounds 
show an aromatic ring, a two-atom linker and a five or six member 
ring. Hybridization strategies have been the basis for the design of 
new chemical entities (5). One problem that has been detected in this 
type of compounds is poor penetration of acid derivatives through 
the Mtb cell wall. It is suggested that these compounds may act as 
prodrugs when ester derivatives generate acid derivatives (5). SAR 
studies of these compounds show that when a methyl group replaces 
a trifluoromethyl group, it is 10 times less active, suggesting that 
electronic effects may play an important role in anti-TB activity. 
Moreover, steric effects can affect anti-TB activity. Subsequently, 
making use of drug design strategies, the authors included ester 
bioisosteres, such as amides and oxadiazole, although none of these 
bioisosteres showed better activity than ester derivatives. It was 
determined that 2 and 8-trifluoromethyl groups on quinoline ring (5) 
are essential for anti-TB activity against replicative bacteria.[52] 
The quinoline and oxazole ring hybridization has been 
used to develop a series of new anti-TB agents (6) which have good 
activity due to the presence of aryl substituents at 2-position on 
quinoline ring. The studies show that the introduction of a 1,3-
oxazole ring significantly increases activity, obtaining compounds 
that are more potent than INH.[49] In search of a new moiety that 
confers anti-TB activity with low cytotoxicity, Yang and colleagues 
reported methoxybenzofuro[2,3-b]quinoline derivatives (7), 
compounds that have a potent Mtb growth inhibition of 99% at low 
concentrations (0.20 μg/mL) and very low cytotoxicity against VERO 
cells with an Inhibitor concentration 50 (IC50) value of > 30.00 
μg/mL.[53] Several studies have analyzed alterations in the 
quinolone ring, mainly at 3,6 and 7- position. A new strategy for anti-
TB agent development, they made a modification in the 2-position, 
including an aliphatic side chain with various degrees of 
unsaturation, lengths chains, and double bond positions (8). Their 
results showed that increasing the chain length enhances anti-TB 
activity, showing optimal activity with 14 C atoms. If there is an 
increase of more carbon atoms in the chain, activity decreases 
dramatically. This behavior has also been described for ciprofloxacin 
derivatives where lipophilicity could play an important role in anti-
TB activity. The saturated aliphatic chain has less activity than 
unsaturated analogues. This means that unsaturation of an aliphatic 
chain is an essential structure for in vitro anti-TB activity.[54] 
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  The 5-[(E)-2-arylethenyl]-3-isoxazolecarboxylic acid alkyl 
ester derivatives and found them as a promising anti-TB agents. 
Among all, compound 5-[(E)-2-(6-methoxy-4-quinolinyl) ethenyl]-3-
isoxazolecarboxylic acid butyl ester (9) showed the best activity 
against Mtb H37Rv with a MIC1.8 μM. This comound showed almost 
equal potency with standard drugs (INH, RMP) in terms of activity 
and cytotoxicity.[55] A series of 3H-1,3,4-Oxadiazole-2-thione and 
3H-1,3,4-oxadiazol-2-one derivatives and tested for their in vitro 
anti-TB activity against Mtb H37Rv. Among both the series, 
oxadiazolone derivatives 10 showed an interesting anti-TB activity of 
MIC 1.25 μg/mL, while the corresponding thione derivatives showed 
poor activity.[56] 
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R=tetrahydroisoquinoline 
The quinoline derivatives to be evaluated against TB were 
quinoline based malaria drugs, such as quinine, chloroquine, 
mefloquine, primaquine, and amodiaquine which possessed 
moderate biological activity against TB. In adition, indentification of 
new promising quinoline based anti-TB agents, 2,8- dicyclopentyl-4-
methylquinoline (DCMQ, 11).[44] and Diarylquinoline (TMC207)[31] 
have definitely initiated the optimization of quinoline for 
antitubercular drugs. In this concern, 1-(5-isoquinoline sulfonyl)-2-
methylpiperazine (12), a protein kinase inhibitor for its anti-TBr 
profile and found to inhibit the growth of two different mycobacterial 
strains, the slow-growing M. bovis Bacille Calmette Guerin (BCG) and 
the fast-growing saprophyte M. smegmatis mc2 155, in a dose-
dependent manner. While screening for the effect of kinase inhibitors 
on mycobacterial growth, millimolar concentrations of 12 induced a 
40% decrease in the growth of M. bovis BCG when measured as a 
function of oxidative phosphorylation. Compound 12 induced 
decreases in growth was shown to involve a 2-log fold decrease in the 
viable counts of M. smegmatis within a 48h period and a 50% 
reduction in the number of BCG viable counts within a 10-day period. 
Micromolar concentrations of 12 induced a significant decrease in 
the activity of the Mtb protein serine/threonine kinase (PSTK) PknB. 
The inhibition of mycobacterial growth as well as the inhibition of a 
representative Mtb protein serine/threonine kinase PknB suggests 
that conventional PSTK inhibitors can be used to study the role that 
the mycobacterial PSTK family plays in controlling bacterial 
growth.[57] A series of quinolinyl hydrazones and majority of the 
tested compounds showed an inhibitory activity between 95 and 
100%. The most potent compounds of the series (13a-c) were having 
a MIC of 0.78μg/mL. These results indicated that the activity was 
significantly affected by substituents both on the quinoline nucleus 
and hydrazinoic moiety. On quinoline nucleus the most effective 
substituents resulted were 6-cyclohexyl, 7-methoxy or ethoxy and 7-
chloro groups. Similarly, for the hydrazinoic moiety greater 
effectiveness resulted for para and ortho-methoxynaphthyl 
substituents whereas disubstitution with chlorine resulted in inactive 
compounds.[48] 
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aR=H, R1=7-OCH3; b R=CH3 R1=6-n-OC4H9; cR=CH3, R=7-Cl 
 
Inspired with the activity profile of DCMQ (11) four new 
series of the ring-substituted quinoline carbohydrazides. Of these 3-
quinolinehydrazides and N2-alkyl/N2,N2-dialkyl/N2-aryl-4-(1-
adamantyl)-2-quinolinecarboxamides showed moderate activity of 
MIC in the range of 6.25-3.125 μg/mL against Mtb H37Rv. The most 
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active compounds were adamantly derivatives (14a and 14b) 
exhibited MIC of 3.125 μg/mL. Whereas, a number of thirty-three 
quinoline derivatives based on TMC207 and found a molecule (15) 
active with a MIC=3.12 μg/mL.[58,59] With the same interest, 3-
benzyl-6-bromo-2-methoxy-quinolines and amides of 2-[(6-bromo-2-
methoxy-quinolin-3-yl)-phenylmethyl]-malonic acid monomethyl 
ester. Four compounds (16a-d) showed moderate activity of MIC 
6.25 μg/mL against Mtb H37Rv.[19,20] A series of substituted 
quinolinyl chalcones and substituted quinolinyl pyrimidines and 
evaluated for their in vitro anti-TB activity against Mtb H37Rv. 
Among both the series, chalcone derivatives 17a and 17b have 
shown anti-TB activity of MIC 3.12 μg/mL and were nontoxic against 
VERO, MBMDM cell lines.[60] 
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16a-d;  aR=imidazolyl; bR=C-
(Thiophen-2-yl)-methyl amine; 
cR=Pyrazolyl; dR=6-
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N
HN
O
R
Cl  
13a and b; aR=2,3-dimethoxy; 
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The anti-TB potential of NAS-91 (18) and found that NAS-
91 has multiple targets, which is particularly desirable for avoiding 
the emergence of resistant strains of Mtb. Therefore, NAS-91 
represents a potent pharmacophore and appears to be a promising 
lead compound for future inhibitor development against TB.[61] 
Quinoline-3-carbohydrazone derivatives and screened for their 
antitubercular efficacy. Among all, two compounds (19a and 19b) 
have shown promising activity with a MIC 0.625, 2.5 and 1.25μg/mL 
against Mtb H37Rv, M. smegmatis and M. fortuitum respectively. 
These compounds have shown almost equal potency similar to that of 
standard rifampicin.[43] Whereas in the series of 4-
quinolylhydrazones, the most active compound (20) displayed an 
anti-TB activity of MIC 0.6μM and selectivity index 2.27.[62] 
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The 7-chloro-4-quinolinylhydrazone derivatives and found 
three molecules (21a-c) with a moderate anti-TB activity with a MIC 
2.5 μg/mL. These compounds were found to be nontoxic against J774 
cell line up to the concentration 100 μg/mL.[63] In search of new 
potent quinoline derivatives consisting of triazolo, ureido and 
thioureido substituents at C-6 position. Of these, ureido derivative 
(22a) and triazolo derivative (22b) have shown moderate activity of 
MIC 3.125μg/mL against Mtb H37Rv.[20] With the same motivation, 
a novel series of amino acid conjugates of 4-(adamantan-1-yl) group 
containing quinolines. The most active nontoxic compound (23) of 
the series exhibited increased potency of 1 μg/mL against Mtb H37Rv 
and 3.125μg/mL against drug-resistant strain, in comparison to 
molecules (22a and 22b).[64] The quinoline-based derivatives were 
evaluated for their anti-TB efficiency. Among all, compound 24 has 
shown remarkable activity of MIC 0.77 μM against Mtb H37Rv and 
0.99-1.55μM against drug-resistant strains.[65] The isoxazole based 
quinoline derivatives and found a lead molecule 25, which showed 
MIC of 0.2 μM and 2.6 μM against Mtb H37Rv.[66] Thus, optimization 
of quinolines for the development of anti-TB agents is a fruitful 
approach. 
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4. Conclusion 
Tuberculosis remains the leading infectious disease 
worldwide, despite the availability of TB chemotherapy. Structure-
based drug design strategies have allowed the discovery of new anti-
TB drugs. These are increasingly receiving more attention, and a 
large number of new compounds or derivatives from existing drugs 
are under investigation. With this and a better understanding of the 
unique biology of TB, more targets will be validated, and hopefully a 
pattern will emerge that will help us reach the goals of more potent 
compounds that allow multiple stages and drug targets to be 
addressed. 
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